ACCESS CLINICAL TRIAL PUBLICATIONS FOR TOUJEO®
Toujeo® has been studied versus Lantus® (insulin glargine injection) 100 Units/mL in four pivotal clinical trials (the EDITION study program)a involving more than 3000 patients and in two euglycemic clamp studies to assess pharmacokinetics (PK) and pharmacodynamics (PD).1-7
Use the links below to read the study abstracts at PubMed.gov.
aAll studies in the EDITION clinical program were 26-week, open-label, controlled, titrate-to-target, noninferiority studies in adults with diabetes not at A1C goal (range: 7% to 10% or 11%), randomized to Toujeo® or Lantus® once daily. All patients were titrated to an FPG goal of 80-100 mg/dL (T2DM) or 80-130 mg/dL (T1DM).1-5